Thursday, October 23, 2014 Last update: 1:33 AM - Covering Large & Obscure Tech Companies Since 1996

Xcovery Announces Presentation at the 2014 American Society of Clinical Oncology Annual Meeting

Companies mentioned in this article: Xcovery Xcovery

WEST PALM BEACH, Fla. -- (BUSINESS WIRE) -- Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced the scheduled poster presentation of preliminary data from the Phase 1 trial of investigational agent X-396 in patients with solid tumors at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30 - June 3, 2014.

Preliminary Phase 1 Results of X-396 in ALK+ NSCLC
Title: A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.
Abstract Number: 8030^
Presenter: Leora Horn, M.D., M.Sc., Vanderbilt-Ingram Cancer Center

Poster Highlights Session: Lung Cancer - Non-small Cell Metastatic
Date & Time: Tuesday June 3, 8:00 a.m. - 11:00 a.m. (CT)
Location: E354b

Time 2: Tuesday June 3, 11:30 a.m. - 12:45 p.m. (CT)
Location 2: E450

About X-396
Xcovery has developed X-396 for the treatment of solid tumors where anaplastic lymphoma kinase (ALK) is deregulated. X-396 has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. X-396 has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma. Importantly, X-396 has shown activity in ALK mutations that confer resistance to other small molecule ALK inhibitors. These data in conjunction with preliminary toxicology and pharmacokinetic data suggest that X-396 should be an effective, well tolerated oral treatment for ALK positive NSCLC, Lymphoma, and neuroblastoma.

Xcovery initiated the Phase I first-in-human clinical trial in June 2012 to study X-396 in advanced solid tumors. Preliminary results in ALK+ NSCLC will be presented at the meeting.

About Xcovery
Xcovery is a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer. Founded by Sheridan G. Snyder and Chris Liang, PhD, Xcovery’s vision is to successfully develop innovative oncology therapies to optimize patient outcomes. Through innovative drug design, Xcovery has developed a comprehensive pipeline of oncology therapies that target a wide range of advanced tumors. For more information, please visit

Copyright © Business Wire 2014

Media Contact:
LaVoie Health Science
David Connolly, 617-374-8800 x108
Business Development Contact:
Cheryl Calhoun, 561-659-1945
Vice President